101 related articles for article (PubMed ID: 12547610)
1. Adjuvant activity of peptidoglycan monomer and its metabolic products.
Halassy B; Krstanović M; Frkanec R; Tomasić J
Vaccine; 2003 Feb; 21(9-10):971-6. PubMed ID: 12547610
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the effects of peptidoglycan monomer and structurally related adamantyltripeptides on humoral immune response to ovalbumin in the mouse.
Tomasić J; Hanzl-Dujmović I; Spoljar B; Vranesić B; Santak M; Jovicić A
Vaccine; 2000 Jan; 18(13):1236-43. PubMed ID: 10649625
[TBL] [Abstract][Full Text] [Related]
3. Effect of liposomal formulations and immunostimulating peptidoglycan monomer (PGM) on the immune reaction to ovalbumin in mice.
Habjanec L; Frkanec R; Halassy B; Tomasić J
J Liposome Res; 2006; 16(1):1-16. PubMed ID: 16556546
[TBL] [Abstract][Full Text] [Related]
4. Influence of adjuvant-active peptidoglycan monomer on specific T cell responses in mice.
Halassy Spoljar B; Cimbora T; Hanzl-Dujmović I; Dojnović B; Sabioncello A; Krstanović M; Tomasić J
Vaccine; 2002 Oct; 20(29-30):3543-50. PubMed ID: 12297400
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of structurally related peptidoglycan monomer and muramyl dipeptide on humoral IgG immune response to ovalbumin in mouse.
Habjanec L; Halassy B; Tomasić J
Int Immunopharmacol; 2010 Jul; 10(7):751-9. PubMed ID: 20403461
[TBL] [Abstract][Full Text] [Related]
6. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens.
Fast DJ; Vosika GJ
Vaccine; 1997 Nov; 15(16):1748-52. PubMed ID: 9364678
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer.
Habjanec L; Halassy B; Tomasić J
Int Immunopharmacol; 2008 May; 8(5):717-24. PubMed ID: 18387514
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel adamantylacetyl derivative of peptidoglycan monomer--biological evaluation of immunomodulatory peptidoglycan monomer and respective derivatives with lipophilic substituents on amino group.
Ljevaković D; Tomasić J; Sporec V; Spoljar BH; Hanzl-Dujmovic I
Bioorg Med Chem; 2000 Oct; 8(10):2441-9. PubMed ID: 11058039
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of an immunomodulator peptidoglycan monomer in mice after intravenous administration.
Ladesić B; Perović S; Hrsak I
Int J Immunopharmacol; 1993 Feb; 15(2):145-50. PubMed ID: 8468117
[TBL] [Abstract][Full Text] [Related]
10. Immunoregulating effects of peptidoglycan monomer linked with zinc in adult mice.
Radoŝević-Staŝić B; Trobonjaĉa Z; Petković M; Milin C; Cuk M; Muhvić D; Ravlić-Gulan J; Marić I; Rukavina D
Int Arch Allergy Immunol; 1995 Mar; 106(3):219-28. PubMed ID: 7888784
[TBL] [Abstract][Full Text] [Related]
11. [Structure-functional study of glycosaminylmuramoyl peptides. The effect of chemical modification of N-acetylglucosaminyl-N-acetylmuramoyldipeptide on its immunomodulating properties in vivo and in vitro].
Meshcheriakova EA; Gur'ianova SV; Makarov EA; Andronova TM; Ivanov VT
Bioorg Khim; 1991 Sep; 17(9):1157-65. PubMed ID: 1807252
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro modulation of NK and ADCC activities of mouse spleen cells by peptidoglycan monomer (PGM).
Gabrilovac J; Tomasić J; Boranić M; Martin-Kleiner I; Osmak M
Res Exp Med (Berl); 1989; 189(4):265-73. PubMed ID: 2813963
[TBL] [Abstract][Full Text] [Related]
13. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
14. Relationship of metabolism and immunostimulating activity of peptidoglycan monomer in mice after three different routes of administration.
Valinger Z; Ladesić B; Hrsak I; Tomasić J
Int J Immunopharmacol; 1987; 9(3):325-32. PubMed ID: 3610420
[TBL] [Abstract][Full Text] [Related]
15. The metabolic fate of 14C-labeled immunoadjuvant peptidoglycan monomer. II. In vitro studies.
Ladesić B; Tomasić J; Kveder S; Hrsak I
Biochim Biophys Acta; 1981 Nov; 678(1):12-7. PubMed ID: 6118181
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of NKT and NK cell-mediated cytotoxicity by peptidoglycan monomer linked with zinc.
Mrakovcić-Sutić I; Radosević-Stasić B; Simin M; Muhvić D; Rukavina D
Mediators Inflamm; 2002 Apr; 11(2):129-35. PubMed ID: 12061425
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mouse and rabbit model for the assessment of strong PGM-containing oil-based adjuvants.
Habjanec L; Halassy B; Vdović V; Balija ML; Tomasić J
Vet Immunol Immunopathol; 2008 Feb; 121(3-4):232-40. PubMed ID: 17996307
[TBL] [Abstract][Full Text] [Related]
18. Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.
Chen N; Johnson MM; Collier MA; Gallovic MD; Bachelder EM; Ainslie KM
J Control Release; 2018 Mar; 273():147-159. PubMed ID: 29407676
[TBL] [Abstract][Full Text] [Related]
19. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits.
Halassy B; Vdović V; Habjanec L; Balija ML; Gebauer B; Sabioncello A; Santek T; Tomasić J
Vaccine; 2007 Apr; 25(17):3475-81. PubMed ID: 17239503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
